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Abstract: Tumor recurrence is the main challenge in glioblastoma (GBM) treatment. Gold standard
therapy temozolomide (TMZ) is known to induce upregulation of IL8/CXCL2/CXCR2 signaling
that promotes tumor progression and angiogenesis. Our aim was to verify the alterations on this
signaling pathway in human GBM recurrence and to investigate the impact of TMZ in particular.
Furthermore, a combi-therapy of TMZ and CXCR2 antagonization was established to assess the
efficacy and tolerability. First, we analyzed 76 matched primary and recurrent GBM samples with
regard to various histological aspects with a focus on the role of TMZ treatment and the assessment of
predictors of overall survival (OS). Second, the combi-therapy with TMZ and CXCR2-antagonization
was evaluated in a syngeneic mouse tumor model with in-depth immunohistological investigations
and subsequent gene expression analyses. We observed a significantly decreased infiltration of
tumor-associated microglia/macrophages (TAM) in recurrent tumors, while a high TAM infiltration
in primary tumors was associated with a reduced OS. Additionally, more patients expressed IL8 in
recurrent tumors and TMZ therapy maintained CXCL2 expression. In mice, enhanced anti-tumoral
effects were observed after combi-therapy. In conclusion, high TAM infiltration predicts a survival
disadvantage, supporting findings of the tumor-promoting phenotype of TAMs. Furthermore, the
combination therapy seemed to be promising to overcome CXCR2-mediated resistance.
Keywords: glioblastoma; TAM; CXCR2; CXCL8; IL8; CXCL2; antiangiogenic therapy; combination
therapy; temozolomide; SB225002
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1. Introduction
Glioblastoma (GBM) is the most common malignant brain tumor in adults [1,2]. The
standard of care therapy consists of surgical removal of the tumor, followed by concomitant
radio-chemotherapy and adjuvant chemotherapy with temozolomide (TMZ) [2–4]. Even
with this highly aggressive standard of care therapy, a median survival of only 15 months
is achieved [5], since GBM is known for a rapid development of resistance to standard
therapy with tumor recurrence [6–10]. One of the challenges to overcome therapy resis-
tance is the inter- and intratumoral heterogeneity [10–12]. Apart from glioma cells and
glioma stem cells, myeloid cells, specifically tumor-associated microglia and macrophages
(TAMs), have been shown to act as a driving force of tumor growth and intratumoral
diversity [13,14]. Making up for 30–50%, TAMs represent a large proportion of the tumor
mass and shape the tumor microenvironment by secreting chemokines, such as CXCL2 and
IL8, and growth factors like VEGF and thus contribute to tumor angiogenesis that sustains
tumor growth [13,15–19]. As VEGF is overexpressed in GBM [20], and it being one of the
most important proangiogenic molecules, anti-VEGF/VEGFR treatment was developed
to overcome resistance [19,21,22]. However, promising preclinical findings could only be
partially reproduced in clinical studies, and anti-VEGF/VEGFR treatment failed to prolong
patients’ overall survival (OS) [21–24]. One further possible resistance mechanism is the
activation of alternative proangiogenic molecules like CXCL2 and IL8 that are also secreted
by TAMs [25,26]. These chemokines and their respective receptor CXCR2 play a central
role in GBM progression and are associated with a reduced OS [25–28]. Furthermore, they
mediate tumor angiogenesis [25,29] and CXCR2 has been shown to be a driving force
on the vascular mimicry (VM) formation in GBM patients, indicating a key role of this
signaling pathway in the tumor blood supply [25,30].
Importantly, about one-third of TMZ-naïve GBM patients and two-thirds of 17 matched
patients overexpressed IL8 in recurrent tumors after TMZ treatment [26,28]. An overex-
pression of CXCL2 was also observed similar to IL8 in 134 TMZ-naïve GBM patients [26].
Additionally, both IL8 and CXCL2 upregulation was observed in vitro after exposing
glioma cells to TMZ, which suggests a potential role of the CXCR2 signaling pathway
in the development of resistance against TMZ [31]. Thus, CXCR2 signaling represents a
promising additional therapeutical target in GBM treatment to overcome TMZ-induced
resistance, as single therapies often fail to target all tumor cells due to GBM heterogene-
ity [2–4]. Recent studies have also shown that combinational approaches exceed the efficacy
of sole administration, especially when targeting chemokine signaling axes in addition
to the standard of care therapy [32]. In this regard, we recently demonstrated an efficient
CXCR2 antagonization with SB225002 (SB) with a significantly reduced tumor volume,
decreased vessel density, and reduced TAM infiltration in an in vivo GL261 syngeneic
mouse model [6–10]. This treatment approach could be combined with TMZ accordingly.
However, only little is known about the impact TMZ might have on the CXCL2, IL8, and
CXCR2 expression and on TAMs as a source of these chemokines in GBM during the
development of resistance in vivo. Therefore, firstly, we aimed to investigate alterations of
TAM infiltration and the CXCR2 signaling pathway in recurrent GBMs in comparison to
their matched primary tumors. Secondly, we stratified patients according to the received
therapy to assess the effect of TMZ in particular on the CXCR2 signaling pathway and
lastly, we investigated the efficacy of TMZ combined with CXCR2 antagonization (SB)
compared to TMZ alone in a preclinical syngeneic orthotopic mouse model.
2. Results
2.1. Comparison of Matched Primary and Recurrent GBM Tumors
2.1.1. Patient and Tumor Characteristics
To assess general differences between primary and recurrent GBM and TMZ therapy-
induced changes, we evaluated a total of 76 tissue samples from 38 GBM patients with
matched primary and recurrent tumors (Table 1). The mean age of the patients at diagnosis
of the primary tumor was 58.7 years, and 59.6 years at diagnosis of the recurrent tumor.
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One-third of the patients were female. Median PFS was 9 months (1st quartile: 15.3,
3rd quartile: 5.4) and median OS was 17 months (1st quartile: 29.7, 3rd quartile: 13.5).
A total of 18 (47%) patients received more than 4 cycles of TMZ. We then assessed the
clinical routine histopathological tumor features that are demonstrated in detail in Table 1.
Almost half of the patients (42%) showed a hypermethylated MGMT promotor. MGMT
methylation positively correlated with a longer PFS and OS as known from the literature
(Supplementary Materials Figure S1a,b) [33,34]. Apart from one patient, all patients carried
an IDHwt gene and there were no obvious differences in p53 accumulation in primary and
recurrent GBMs (Table 1). With regard to proliferation, most recurrent tumors exerted the
same activity as primary tumors.
Table 1. Patients’ characteristics.
Patient Features n
female 13 * (34%)
male 25 * (66%)
mean age at diagnosis in years 59 ± 13
median age at diagnosis in years 61 (21–82)
Treatment
primary tumor resection 38 * (100%)
tmz cycles ≥4 18 * (47%)
1–3 8 * (21%)
0 12 * (32%)
Survival
PFS (months) mean 12 ± 9
median 9 (2–36)
OS (months) mean 19 ± 10
median 17 (2.4–42.5)
Histopathologic Features
GBM samples 76 (100%)
MGMT status unmethylated 22 (58%) *
methylated 16 (42%) *
IDH1 status mutated 1 (2.6%) *
wildtype 37 (97.4%) *
Ki-67 (mitotic index) pGBM rGBM #
<10% 2 (5.3%) 7 (20%)
10–30% 32 (84.2%) 26 (74.3%)
>30% 4 (10.5%) 2 (5.7%)
p53 accumulation positive 34 (89.5%) 26 (81.25%)
negative 4 (10.5%) 6 (18.75%)
pGBM = primary GBM, rGBM = recurrent GBM, PFS = progression-free survival, OS = overall survival; * matched
patients, # data was not available for all patients.
2.1.2. TAM Infiltration Is Significantly Reduced in Recurrent Tumors and Very High
Infiltration Leads to a Reduced PFS
Since GBMs are infiltrated by a large number of myeloid cells, especially TAMs that
make up to 30–50% of the tumor microenvironment [13,14], we first focused on these
cells. TAMs are known to exert both pro- [35–37] and antitumoral functions [38]. Impor-
tantly, they express proangiogenic molecules like VEGF [13,15,16] and CXCL2 [15,17] and
thus contribute to maintaining tumor growth. To analyze the amount of TAMs within
the tumors, tissue sections were stained for IBA1 (Figure 1a). The number of TAMs
was significantly reduced by 41% in recurrent tumors in comparison to primary tumors
(p = 0.0004; Figure 1b). A subgroup analysis of patients with a very high infiltration
(>1000 cells/mm2), high infiltration (520–1000 cells/mm2), and low infiltration
(<520 cells/mm2) was then performed. Kaplan–Meier curves revealed that patients with a
very high TAM infiltration had a significantly reduced PFS compared to high infiltration
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(Figure 1c,d; very high vs. high p = 0.0079; very high vs. low p = 0.1029; high vs. low
p = 0.6418), while no significant differences could be detected with regard to the OS within
the categorized TAM infiltration groups. Interestingly, the median survival of patients
within the very high (6.25 months) and the low infiltration group (7.63 months) was less
than in the high infiltration group (16.01 months); however, this did not reach the level of
significance (OS: very high vs. high p = 0.1081; very high vs. low p = 0.1538; high vs. low
p = 0.9790).
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Figure 1. TAM infiltration is significantly reduced in recurrent tumors and a very high infiltration in primary tumors is
associated with a shortened PFS. (a) Representative immunofluorescence staining of TAMs (IBA1) in magenta and cell
nuclei (DAPI) in blue of primary and recurrent tumors of GBM patients, scale bars 100 µm. (b) Comparison of the number
of TAMs in primary and recurrent tumors showing a significant reduction in recurrent tumors. All primary tumors are
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2.1.3. Comparable Angiogenic Activity in Primary and Recurrent Tumors
Besides high TAM infiltration, GBM is also characterized by a strong angiogenic
activity [19]. Thus, we investigated the expression of VEGF (Figure 2a,b) and the alternative
proangiogenic factors CXCL2 (Figure 2c,d) and IL8 (Figure 2e,f) amongst the matched
tumor samples. While there were no changes in the expression of VEGF, CXCL2 expression
was significantly reduced in recurrent GBMs (p = 0.0280) compared to primary tumors.
Interestingly, all patients expressed CXCL2 in the primary tumors while IL8 was only
detected in 43% (n = 16) of primary GBMs. In recurrent tumors, IL8 expression was
significantly increased to 67.5% (n = 25) (p = 0.0438). To further evaluate the influence
of alterations in recurrent tumor vascularization, all tumor sections were stained for
the endothelial cell marker CD31. The vessel count in recurrent tumors did not differ
from primary tumors (Figure 2g,h; pGBM: 41/mm2 vs. rGBM: 34/mm2). As CXCR2 is
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preferentially expressed by endothelial cells, co-staining of CD31 and CXCR2 was carried
out (Figure 2i). However, no differences in the percentage of CXCR2-positive blood vessels
could be detected between primary and recurrent GBM tumor samples (Figure 2j; pGBM:
36% vs. rGBM: 40%).
In summary, recurrent GBM tumors were different to their matched primary coun-
terpart with regard to TAM infiltration and the expression of the alternative proangiogenic
molecules CXCL2 and IL8, while VEGF and the tumor vascularization remained comparable.
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2.1.4. TAMs Serve as a Predictor for a Reduced OS
To further assess the impact of the examined parameters on patient survival, an
explorative cox regression analysis was carried out. The influence of the TAM infiltration,
the expression of VEGF, CXCL2, and IL8 as well as vascular parameters, such as the vessel
density, vessel area, including CXCR2+ vessels and their impact on the OS, and the PFS,
were examined. In order to evaluate the effect of temozolomide on patient survival, the
received temozolomide cycles were included in this analysis as an independent parameter,
since the number of the TMZ cycles was not uniform in our patient cohort. Furthermore,
MGMT hypermethylation is associated with a prolonged OS as described in the literature
and confirmed in our cohort [33,34] (Supplementary Materials Figure S1a,b). Therefore,
the MGMT status was included as well.
The univariable analysis of the TAM infiltration showed that it is a positive predictor
for a significantly reduced OS (p = 0.02). The multiple analysis then confirmed that TAM
infiltration is an independent positive predictor (p = 0.02) and that the CXCR2+ vessel
area is an independent negative predictor of overall survival in GBM patients as well
(p = 0.04) (Table 2). Therefore, patients with a greater CXCR2+ vessel area may survive
longer (Table 2). Subsequently, we performed a subgroup analysis that only included
patients with CXCR2+ vessels (Supplementary Materials Table S2). Here, multiple analysis
of TAM infiltration, received TMZ cycles, and CXCR2+ vessel area did not confirm the
CXCR2+ vessel area as an independent negative predictor of OS (Supplementary Materials
Table S2). Th amount of re eiv d TMZ cycles and the hypermethylation of MGMT di no
predict the OS in this study (Tabl 2). However, the number of received TMZ cycles served
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as a negative predictor of recurrence (p = 0.02). Consequently, patients receiving more TMZ
cycles had a later recurrence in our cohort, confirming the protective role of TMZ treatment
against tumor progression (Table 3). The only other predictor for a prolonged PFS was
MGMT methylation. Both factors remained significant in the multiple analyses (Table 3).
Table 2. Cox regression analysis of the overall survival.
OS Univariable Analysis Multiple Analysis
p-Value HR 95% CI p-Value HR 95% CI
pIBA1 0.02 1.01 1.00–1.03 0.02 1.01 1.00–1.03
pVEGF 0.57 1.07 0.85–1.33
pCXCL2 0.60 1.04 0.85–1.22
pIL8 0.57 0.80 0.37–1.73
pvessel count 0.77 1.00 0.99–1.02
pvessel area 0.45 0.00 0.00–1,873,571.60
pCXCR2+ vessels 0.72 1.00 0.99–1.02
pCXCR2+ vessel area 0.12 0.00 0.00–8874 × 1022 0.04 0.00 0.00–0.001
TMZ cycles 0.20 0.94 0.86–1.03 0.07 0.86 0.73–1.01
MGMT methylation 0.30 0.99 0.96–1.01
p = primary tumor; TMZ = temozolomide; HR = Hazard Ratio; 95% CI = 95% confidence interval.
Table 3. Cox regression analysis of the progression-free survival.
PFS Univariable Analysis Multiple Analysis
p-Value HR 95% CI p-Value HR 95% CI
pIBA1 0.60 1.00 0.99–1.00
pVEGF 0.35 0.90 0.73–1.12
pCXCL2 0.29 1.08 0.93–1.26
pIL8 0.60 0.82 0.39–1.72
pvessel count 0.48 1.01 0.99–1.02
pvessel area 0.49 1114.81 0.00–6.63 × 1011
pCXCR2+ vessels 0.25 0.99 0.98–1.01
pCXCR2+ vessel area 0.32 0.00 0.00–4.34 × 1041
TMZ cycles 0.01 0.86 0.77–0.96 0.02 0.87 0.78–0.98
MGMT methylation 0.04 0.97 0.94–0.99 0.09 0.98 0.95–1.00
p = primary tumor; TMZ = temozolomide; HR = Hazard Ratio; 95% CI = 95% confidence interval.
2.2. Potential Effects of TMZ Treatment on the Tumor Microenvironment
Expression of Proangiogenic Molecules and Vascularization in GBM Patients Is Mostly Not
Affected by TMZ Therapy
TMZ is known to have a high impact on prolonging patients’ lives [2]. This was also
confirmed by our study as a higher number of received TMZ cycles predicted a longer
progression-free survival. Furthermore, we observed significant differences between
primary and recurrent tumors with regard to TAM infiltration and expression of the
proangiogenic factors CXCL2 and IL8. It has been shown that gene expression of TAMs
differed between matched primary and recurrent tumors (n = 19); however, it is not known
whether TAM reduction and alterations in angiogenic pathways in recurrent tumors are
associated with the duration of TMZ treatment [39]. Therefore, we then aimed to analyze
the role of TMZ on these alterations in particular. In our cohort, all patients underwent
a primary tumor resection followed by radio-chemotherapy (n = 32; 84%) or in a few
cases sole radiotherapy (n = 4; 10%). However, as the de facto applied treatment was
not uniform amongst the patients regarding the number of TMZ cycles, we divided the
patient cohort into two groups as described in the methods in order to assess the effects
of TMZ therapy, fulfilling almost the standard adjuvant regimen (standard: TMZ≥4) in
comparison to none or only few applied cycles (not standard: TMZ≤3). Relevant clinical
comparison of both groups is presented in Supplementary Materials Table S1. To evaluate
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whether the two groups were different at the point of diagnosis, patient age, gender, and
primary tumor characteristics including MGMT status and IDH and p53 accumulation
were assessed and showed no significant differences (Supplementary Materials Table S1).
Kaplan–Meier curves were generated and showed a distinct prolonged PFS (standard:
13.7 vs. 5.6 months; p = 0.0002) of the standard group (Figure 3a). However, the overall
survival was not significantly different (standard: 28.2 vs. not standard: 14.6 months;
p = 0.0525) (Figure 3b). We then evaluated the impact of TMZ therapy on the infiltration
of TAMs, the expression of proangiogenic molecules, and the vasculature in primary and
recurrent GBMs and compared both groups. First of all, the infiltration of TAMs remained
significantly lower in recurrent tumors compared to primary tumors regardless of the
treatment groups (standard: p = 0.0037; not standard: p = 0.0356; Figure 3c). As TAMs
serve as a source of the proangiogenic molecule CXCL2, TAMs that showed expression of
CXCL2 were counted in particular. In the recurrent tumors of both groups, the amount of
CXCL2+ TAMs per mm2 and the percentage of CXCL2-expressing TAMs were reduced.
However, this reduction only reached the level of significance in the not standard group
(not standard: CXCL2+ TAMs per mm2: 46% decrease in recurrent tumors, p = 0.0147,
Figure 3d; percentage of CXCL2+ TAMs: 23% decrease in recurrent tumors, p = 0.0383;
Figure 3e and Supplementary Materials Figure S2a,b).
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Figure 3. Influence of TMZ on TAM infiltration, tumor vascularization, and expression of proangiogenic molecules in 
matched primary and recurrent GBMs. (a,b) Kaplan–Meier curves for (a) progression-free (PFS) and (b) overall survival 
(OS) of the subgroup analysis comparing the standard with the not standard group. (c–m) Graphs show the calculation of 
the stained area of TAMs (IBA1) (c–e), proangiogenic molecules VEGF (f), CXCL2 (g), IL8 (h) tumor vessels (CD31) (i–k), 
and CXCR2+ vessels (l,m) on FFPE tissue sections of primary and recurrent tumors of all patients. (c) Graph depicts the 
amount of TAMs in primary and recurrent tumors of both groups, which were significantly reduced in recurrent tumors 
(standard: mean difference: 246.7; 95% confidence interval −400.5 to −92.87; not standard: mean difference: −192.2; 95% 
confidence interval −370.0 to −14.40). (d,e) Graphs depict CXCL2+ TAMs in primary and recurrent tumors of both groups. 
(f–h) Graphs show calculation of the stained area of VEGF (f) and CXCL2 (g) (n = 38; standard: n = 18; not standard: n = 
20). (h) The number of IL8+ patients in primary and recurrent tumors was calculated (n = 38; standard: n = 18; not standard: 
n = 20). (i–k) Graphs depict vessels/mm2 (i), the vessel area/vessel number (j), and vessel area/mm2 (k) (n = 30; standard: n 
= 15; not standard: n = 15). (l,m). The area of CXCR2+ vessels/CXCR2+ vessel number in (l) and the percentage of CXCR2+ 
vessels in relation to all vessels (m) was calculated (n = 28; standard: n = 13; not standard: n = 15). * p < 0.05, ** p < 0.01, *** 
p < 0.001. (c–m) paired Student’s t-test; box plots depicting mean (shown as “+”), median, 1st and 3rd quartile (shown as 
the box) and min to max (shown as the whiskers). 
We then evaluated differences regarding IL8 and CXCL2 expression in recurrent tu-
mors of both groups and also the standard proangiogenic molecule VEGF. IL8 expression 
increased in recurrent tumors independent of the therapeutic regimen (standard: 38% in-
crease, p = 0.2686; not standard: 85% increase, p = 0.05527) (Figure 3h). The area of CXCL2 
expression was only significantly reduced in recurrent tumors of patients in the not stand-
ard group (standard: 10.1% decrease; not standard: 36.5% decrease; p = 0.0055) (Figure 3g). 
Interestingly, 50% of patients within the standard group (TMZ≥4) showed an upregulation 
of CXCL2 in the recurrent tumors. While IL8 and CXCL2 expression was changed in re-
current tumor, there was no significant difference regarding the expression of VEGF (Fig-
ure 3f). Angiogenic molecules promote tumor vascularization. Thus, vessel structures of 
primary and recurrent tumors in both groups were analyzed in addition to the angiogenic 
pathways. The vessel count, vessel size, vessel area as well as CXCR2+ vessels and 
area/CXCR2+ vessel were evaluated. The amount of vessels per mm2 in the recurrent tu-
mors of the standard group was markedly decreased (standard: 28.7% decrease in rGBM; 
p = 0.0369: not standard: 0.5% decrease in rGBM). All other parameters were not differ-
ently affected by the different therapeutic regimes (Figure 3i–m).  
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We then evaluate differences regarding IL8 and CXCL2 expression in recurrent
tumor of both groups and al o the sta ard proangiogenic mol cule VEGF. IL8 expression
increased in recurrent tumo s independent of the therapeutic regimen (standard: 38%
increase, p = 0.2686; not standard: 85% inc ase, p = 0.05527) (Figure 3h). The area of
CXCL2 expression was only significantly reduced in recurrent tumors of patients in the
not standard group (standard: 10.1% decrease; not standard: 36.5% decrease; p = 0.0055)
(Figure 3g). Interestingly, 50% of patients withi the standard group (TMZ≥4) showed an
upregulation of CXCL2 in the recurrent tumors. While IL8 and CXCL2 expression was
changed in recurrent tumor, there was no significant difference regarding the expression
of VEGF (Figure 3f). Angiogenic molecules promote tumor vascularization. Thus, vessel
structures of primary and recurrent tumors in both groups were analyzed in addition to the
angiogenic pathways. The vessel count, vessel size, vessel area as well as CXCR2+ vessels
and area/CXCR2+ vessel were evaluated. The amount of vessels per mm2 in the recurrent
tumors of the standard group was markedly decreased (standard: 28.7% decrease in rGBM;
p = 0.0369: not standard: 0.5% decrease in rGBM). All other parameters were not differently
affected by the different therapeutic regimes (Figure 3i–m).
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2.3. In Vivo Assessment of Combination Therapy with TMZ and SB
The reduced TAM infiltration in recurrent GBM underlines the relevant morphological
differences between primary and recurrent tumors in line with the changed gene profile
of recurrent GBM tumors, as has already been shown [39]. These data reflect the need for
different therapeutic approaches in recurrent tumors. As our data confirmed the crucial
role of TAMs in tumor progression of primary tumors and their association with a reduced
overall survival in GBM patients, TAMs are a suitable target for the initial GBM treatment.
In our previous study, we showed that the local treatment by CXCR2 antagonist SB225002
(SB) significantly reduced the TAM infiltration in an orthotopic glioma mouse model
in vivo [40]. Furthermore, in our patient cohort, CXCL2 was not significantly reduced in
recurrent tumors after therapy according to Stupp’s protocol in contrast to recurrent tumors
of patients who received no or less temozolomide. This finding matched the previously
described TMZ-induced changes in the chemokine network, which could be identified
as a mechanism to the development of therapy resistance [28,31]. Even if only a few
effects of TMZ application were observed on CXCR2 signaling in matched patient samples,
preclinical models showed the efficacy of combined approaches consisting of standard
therapy and additionally targeting chemokine signaling axes [32]. Therefore, combining SB
additionally with TMZ poses a promising therapeutic approach. To validate the treatment
tolerability and the efficacy of combined therapy of TMZ and SB, a GBM mouse model
with GL261 tumor cells was used.
2.3.1. No Adverse Effects by Additional CXCR2 Antagonization with TMZ In Vivo
The combination of SB and TMZ was well tolerated during the treatment period
of seven days. Animals showed no signs of additional distress and did not develop
any side effects. Additionally, the body weight was not influenced by therapy. During
preparation for perfusion, slightly irritated intestines were observed, most likely caused by
intraperitoneal TMZ administration as this was also the case for the sole TMZ group.
2.3.2. Combination Therapy with TMZ and SB Reduces Tumor Volume and Proliferation in
a Syngeneic Orthotopic GBM Mouse Model
Tumor growth was assessed by MRI before starting the treatment on day 14. After
seven days, tumor volume was again assessed by MRI and histological analysis were
conducted. In the combined treatment group, a tumor volume reduction of 75% was
achieved compared to the control group (p = 0.0062, n = 7–8), whereas TMZ alone led
to a reduction of 61% (p = 0.0224, n = 7–8; Figure 4a,b). The additional effect through
adding SB to TMZ was 36% compared to sole TMZ treatment; however, this did not reach a
significant level.
To investigate the underlying mechanisms of tumor volume reduction in detail, the
effects of TMZ and SB on proliferation and apoptosis were investigated. It has already been
shown that both TMZ and SB have an inhibitory influence on the proliferation of tumor
cells [4,40–43]. It was therefore interesting to see whether the effects of both substances
could potentiate one another. In this study, a significantly impaired proliferation could
be observed in both treatment groups compared to the untreated control (TMZ group: by
25%; p = 0.0205, n = 4; TMZ + SB: by 37%; p = 0.002, n = 4; Figure 4c,d). Interestingly,
apoptosis was unaltered in the setting used in this study (Figure 4c,e). However, when the
ratio of apoptotic and proliferating tumor cells was calculated, a shift towards apoptosis
could be detected following combined treatment (compared to control: by 82%; p = 0.0014,
compared to TMZ alone: by 35%; p = 0.0388; n = 4; Figure 4f).
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after the treatment with TMZ and TMZ+SB. (b) Quantitative tumor volumetry showed a significantly reduced tumor 
volume by 75% in the combination group (TMZ+SB) whereas TMZ alone reduced tumor volume by 61% (n = 7–8; * p = 
0.0224; ** p = 0.0062). (c) Representative immunofluorescence staining of each group showing a reduction of proliferation 
in the TMZ and TMZ+SB group while apoptosis seemed to be unaffected (Ki67: green, TUNEL: red, scale bar = 100 µm). 
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** p = 0.0062). (c) Representative immunofluorescence staining of each group showing a reduction of proliferation in
the TMZ and TMZ + SB group while apoptosis seemed to be unaffected (Ki67: green, TUNEL: red, scale bar = 100 µm).
(d) The detailed analysis of proliferation showed significant impairment in both treatment groups. The proliferation was
reduced by 37% in the combination group and 25% in the TMZ group (n = 4; * p = 0.0205; ** p = 0.002; TMZ vs. TMZ + SB,
p = 0.4416). (e) However, apoptosis remained unaltered (n = 4; Control vs. TMZ, p = >0.9999; Control vs. TMZ + SB,
p = 0.1616; TMZ vs. TMZ + SB, p = 0.1204). (f) If the ratio of apoptosis and proliferation was calculated, a significant shift
towards apoptosis could be detected only in the combination group of TMZ + SB225002 (n = 4; * p = 0.0388; ** p = 0.0014).
(g,h) Apoptosis-regulating molecules Bax (proapoptotic) and Bcl2 (antiapoptotic) were unchanged in qRT-PCR analysis
(n = 3–4). (d–f) Graphs depict individual values with additional mean ± standard deviation; bar graphs (g,h) showing
mean ± standard deviation. One-way ANOVA with Bonferroni correction was performed in all analyses.
For further verification of these findings, gene expression analysis of Bax (proapoptotic)
and Bcl2 (antiapoptotic), both regulators of apoptosis, were conducted [44,45]. Within a
treatment period of seven days, Bax and Bcl2 gene expression were not changed by either
of the therapies (Figure 4g,h).
Taken together, the antitumoral effect of combinational treatment on tumor volume
reduction and proliferation exceeded the effect of sole TMZ.
2.3.3. Combination Therapy with TMZ and SB Tends to Diminish Total Tumor
Vascularization While Infiltration of TAMs Was Unaltered
Our data supports the pro-tumoral role of TAMs in GBM pathogenesis as a predictor
for reduced overall survival as demonstrated in the previous section and furthermore our
group has recently reported a decrease in TAMs after sole SB treatment [40]. Based on
these findings, it was of major interest to analyze if TAMs play a role in the additional
anti-tumoral effect of the combination therapy in vivo. However, accumulation of TAMs
was unaltered in vivo amongst all groups within the short observation period (Figure 5a,b).
CXCR2 signaling is involved in central angiogenic cascades and the selective CXCR2
antagonist SB showed antiangiogenic potential in recent studies [25,26,40]. Therefore, we
aimed to investigate tumor vascularization in detail. The question was whether adding
CXCR2 antagonization to TMZ can enhance antiangiogenic efficacy of the therapy. Overall,
we observed an incipient decrease of tumor vascularization, which was most distinctive
in the combined administration of TMZ + SB (Figure 5c–f). In comparison with sole TMZ
and combined treatment, the vessel area and average vessel size were reduced by 36.5%
and 40.5%, respectively (Figure 5d,e). Nevertheless, the threshold of significance was not
crossed. No difference between TMZ and TMZ + SB could be detected with regard to the
vessel count (Figure 5f).
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Figure 5. Therapy-induced effects on TAM accumulation and tumor vascularization. (a) Representative immunofluores-
cence staining showing no differences in TAM accumulation between groups (DAPI: blue, IBA1: green, scale bar = 100 
µm). Additionally, no obvious changes in TAM morphology by therapy were observed as indicated in the magnified 
images. (b) The quantitative analysis of TAM accumulation showed comparable levels between all groups. (c) Representa-
tive immunofluorescence staining showing a tendency of diminished tumor vascularization (CD31: red, scale bar = 100 
µm). (d–f) Quantitative comparison of vessel parameters showed reduced vessel area (calculated as a percentage in rela-
tion to the total analyzed tumor area; n = 4; Control vs. TMZ, p ≥0.9999; Control vs. TMZ+SB, p = 0.3951; TMZ vs. TMZ+SB, 
p = 0.8661) and average vessel size (calculated as total vessel area/vessel number; n = 4; Control vs. TMZ, p = 0.8802; Control 
vs. TMZ+SB, p = 0.2449; TMZ vs. TMZ+SB, p ≥0.9999) which was most markedly in the combination group. Vessel density 
was unchanged in all groups (n = 4; Control vs. TMZ, p = 0.1841; Control vs. TMZ+SB, p = 0.4623; TMZ vs. TMZ+SB, p 
≥0.9999). Graphs depict individual values with additional mean ± standard deviation. One-way ANOVA with Bonferroni 
correction was performed in all analyses. 
2.3.4. CXCR2/CXCL2 Are Upregulated in Murine Tumor Tissue and Decreased by Ther-
apy without Affecting Alternative Signaling Pathways  
An important requirement for investigating the effect of adding the CXCR2 antago-
nist SB to the TMZ standard therapy was the upregulation of the CXCR2 signaling path-
way in our tumors in comparison to healthy brain tissue. Based on qRT-PCR analysis, 
upregulation of Cxcr2 and Cxcl2 were detected in untreated tumor tissue compared to 
contralateral non-tumor tissue (Figure 6a,b). While Cxcr2 was significantly upregulated ≈ 
7-fold (p = 0.0434, n = 4; Figure 6a), Cxcl2 upregulation was measured as 5-fold with a high 
variation of individual values that did not reach the level of significance (n = 4, p = 0.0977; 
Figure 6b). Interestingly, both therapies induced a decrease of Cxcr2 (Control vs. TMZ: 
5.6-fold; Control vs. TMZ+SB: 3.5-fold; n = 3–4; Figure 6c), whereas Cxcl2 expression re-
mained unaffected (Figure 6d). Furthermore, the expression of CXCR2 and CXCL2 were 
verified on the protein level via immunohistological intensity measurements. No differ-
ences could be seen in both therapy groups compared to the control (Figure 6e–h). Im-
portantly, molecule staining showed no group-specific distribution pattern amongst all 
groups (Figure 6e,g). 
Figure 5. Therapy-induced effects on TAM ac umulation and tumor vascularization. ( ) Rep esentative immunofluorescence
staining showing no differences in TAM accumulation between groups (DAPI: blue, IBA1: green, scale bar = 100 µm).
Additionally, no obvious changes in TAM morphology by therapy were observed as indicated in the magnified images.
(b) The quantitative analysis of TAM accumulation showed comparable levels between all groups. (c) Representative
immunofluorescence staining showing a tendency of diminished tumor vascularization (CD31: red, scale bar = 100 µm).
(d–f) Quantitative comparison of vessel parameters showed reduced vessel area (calculated as a percentage in relation to
the total analyzed tumor area; n = 4; Control vs. TMZ, p ≥ 0.9999; Control vs. TMZ + SB, p = 0.3951; TMZ vs. TMZ + SB,
p = 0.8661) and average vessel size (calculated as total vessel area/vessel number; n = 4; Control vs. TMZ, p = 0.8802; Control
vs. TMZ + SB, p = 0.2449; TMZ vs. TMZ + SB, p ≥ 0.9999) which was most markedly in the combination group. Vessel
density was unchanged in all groups (n = 4; Control v . TMZ, p = 0.1841; Control vs. TMZ + SB, p = 0.4623; TMZ vs. TMZ
+ SB, p ≥ 0.9999). Graphs depict individual values with additional mean ± standard deviation. One-way ANOVA with
Bonferroni correction was performed in all analyses.
Overall, we observed a tendency for diminished vessel area and vessel size without
alterations in TAM accumulation after combinational treatment in comparison to sole TMZ.
2.3.4. CXCR2/CXCL2 Are Upregulated in Murine Tumor Tissue and Decreased by
Therapy without Affecting Alternative Signaling Pathways
An important requirement for investigating the effect of adding the CXCR2 antagonist
SB to the TMZ standard therapy was the upregulation of the CXCR2 signaling pathway
in our tumors in comparison to healthy brain tissue. Based on qRT-PCR analysis, upregu-
lation of Cxcr2 and Cxcl2 were detected in untreated tumor tissue compared to contralat-
eral non-tumor tissue (Figure 6a,b). While Cxcr2 was significantly upregulated ≈ 7-fold
(p = 0.0434, n = 4; Figure 6a), Cxcl2 upregulation was measured as 5-fold with a high
variation of individual values that did not reach the level of significance (n = 4, p = 0.0977;
Figure 6b). Interestingly, both therapies induced a decrease of Cxcr2 (Control vs. TMZ:
5.6-fold; Control vs. TMZ + SB: 3.5-fold; n = 3–4; Figure 6c), whereas Cxcl2 expression
remained unaffected (Figure 6d). Furthermore, the expression of CXCR2 and CXCL2
were verified on the protein level via immunohistological intensity measurements. No
differences could be seen in both therapy groups compared to the control (Figure 6e–h).
Importantly, molecule staining showed no group-specific distribution pattern amongst all
groups (Figure 6e,g).
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Figure 6. Upregulation of CXCL2/CXCR2 signaling in tumor tissue and the influence of therapy on CXCR2 signaling and
alternative pathways. (a) Gene expression of Cxcr2 was significantly upregulated (7-fold) in tumor tissue of GL261 mouse
GBMs compared to contralateral brain parenchyma (n = 4; p = 0.0434). (b) Additionally, Cxcl2 was upregulated 5-fold but
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did not a significant level in this study (n = 4; p = 0.0977). (c) The investigation of Cxcr2 showed a therapy-induced decrease
of gene expression under TMZ and TMZ + SB treatment (n = 3–4, Control vs. TMZ, p = 0.0693; Control vs. TMZ + SB
p = 0.1637) but without reaching statistical significance. (d) However, Cxcl2 remained completely unchanged (n = 3–4).
(e–h) Representative immunofluorescence staining of CXCR2 and CXCL2 on the protein level showed no differences or
group-specific distribution patterns amongst all groups (CXCR2: green, CXCL2: red). The measurement of the mean
intensity of immunofluorescence images of both molecules showed no differences of protein expression. All images were
captured with the same exposure time under comparable conditions (n = 4). (i–k) qRT-PCR analysis of the classic angiogenic
pathway with Vegf and its receptors Vegfr1 and Vegfr2 showed no compensatory upregulation during therapy with TMZ
or TMZ + SB (n = 3–4). (l) Gene expression of Cxcr1, which has similar downstream effects as Cxcr2, was also not altered
significantly (n = 3–4). (a–d,i–l) Bar graphs showing mean ± standard deviation; (f,h) graphs depict individual values with
additional mean ± standard deviation; one-way ANOVA with Bonferroni correction was performed in all analyses.
To unravel other therapy-induced changes or compensatory mechanisms that could be
a reason for the only slightly decreased tumor vascularization, further qRT-PCR analyses
were conducted, with a focus on classic proangiogenic molecules, such as Vegf with its
receptors Vegfr1 and Vegfr2 as well as Cxcr1. It is known that the VEGF pathway is
also upregulated in GBM pathogenesis and correlates with tumor vascularization [19,46].
Furthermore, CXCR1 serves as an alternative binding site for CXCR2 ligands, including IL8
and CXCL2, leading to similar effects to CXCR2 after activation [47–50]. After the treatment
period of seven days, no altered gene expression levels of either the Vegf pathway nor
Cxcr1 was detected (Figure 6i–l).
In summary, it can be said that CXCR2 was significantly upregulated in the GL261
GBM tumor model compared to healthy tissue, with a decrease after each therapy. Impor-
tantly, alternative signaling pathways were not altered in vivo.
3. Discussion
Our analysis of 76 matched primary and recurrent GBM samples underlined im-
portant morphological differences between primary and recurrent GBM, with a higher
infiltration of TAMs in the primary tumors. Our data revealed that the infiltration of TAMs
in primary tumors served as a negative predictor for patients´ OS. Only minor possibly
TMZ-induced differences regarding the important vasculogenic and tumorigenic path-
ways, VEGF and CXCR2, in GBM patients could be detected. However, CXCL2 expression
was significantly lower in recurrent tumors of the not standard (TMZ≤3) group, while
IL8 expression rose from 45% (standard) and 42% (not standard) in primary tumors to
61% and 74%, respectively, in recurrent tumors. The combination of TMZ with CXCR2-
antagonization represented a new promising treatment approach in GBM based on the
previous studies [25,26,28,32,40,51–53]. Here, we demonstrated a well-tolerated therapy
regimen with an enhanced reduction of tumor volume and proliferation by adding SB to
the TMZ treatment in a syngeneic orthotopic mouse model.
3.1. Comparison of Matched Primary and Recurrent GBM Tumor Characteristics
To assess whether our matched GBM patient cohort was representative for GBM
patients, clinical characteristics and neuropathological routine diagnostics were analyzed.
The age at diagnosis and the gender distribution in our study cohort was comparable
to previously published data [2,54]. In this study, patients within the standard group
had a median OS of 28.6 months (1st quartile: 31.1, 3rd quartile: 19.9) compared to
14.6 months (1st quartile: 22.0, 3rd quartile: 9.6) within the not standard group. Thus,
this exceeded the expected median OS for both groups, when compared to previous
studies [2,54]. According to the published data, only 20–30% of GBM patients undergo a
second surgical treatment [55], depending on their age and clinical performance status [56].
As the development of tumor recurrence and surgical treatment for both the primary and
recurrent tumors were the main inclusion criteria of this study, the patient selection could be
biased, leading to the positive influence on the OS. Other characteristics that are associated
with a prolonged survival are IDH-1/2 mutations and MGMT hypermethylation [57].
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However, IDH was only mutant in one patient. Previous studies have shown that the
MGMT promoter is hypermethylated in 40–60% of GBM patients, which coincides with
our findings [58]. We could confirm that MGMT methylation positively correlates with PFS
and OS in our patient cohort as previously shown by Radke et al. [34]. Nevertheless, in
contrast to their findings, we did not identify high MGMT methylation as a predictor of
survival, which could be due to the fact that they divided patients into groups according to
the MGMT methylation level [34].
3.2. TAMs Serve as a Negative Predictor of OS in GBM
It is known that the amount of TAMs correlates positively with tumor grade and
malignancy [59,60]. For the first time, we identified TAMs as a negative predictor of
OS in our GBM patient cohort. This is an important finding as several studies suggest
that TAMs exert pro- or anti-tumoral functions depending on their polarization in GBM
(M1 = proinflammatory, antitumoral; M2 = immunosuppressive, protumoral) [13,61–63].
Furthermore, emerging evidence indicates that TAMs acquire different phenotypes depen-
dent on the tumor microenvironment [18,62–65]. However, within the past years, several
research groups have indicated that TAM populations within GBM showed heterogenous
gene expression, which cannot be assigned to the classical M1 or M2 phenotype, but rather
to a specific subtype of protumoral TAMs [18,63,64]. Our findings of TAMs being a negative
predictor of survival support the pro-tumoral phenotype of these myeloid cells in primary
GBM as previously described by others [35–37]. Importantly, a very high infiltration led
to a shorter PFS in our cohort, while the intermediate (high) group had the best median
overall survival, suggesting a required balanced number of TAMs for tumor control. To
clarify this phenomenon, further investigations on TAM gene expression are warranted.
Furthermore, infiltration of TAMs was significantly reduced in the recurrent tumors
compared to their matched primary tumors. A recent study by Fu et al. demonstrated that
the proportion of TAMs in relation to the total amount of immune cells was decreased in
three recurrent GBM samples [66]. As they calculated the proportional amount and only
investigated a small number of patients without using matched primary and recurrent
tumors, our study is the first to report that the amount of TAMs is significantly reduced in
recurrent GBMs in a cohort of 38 matched tumors. Importantly, Hudson et al. demonstrated
that TAMs in primary tumors differ from their counterparts in recurrent tumors in a
matched patient cohort (n = 19) [39]. This, alongside our findings, needs to be taken in
consideration regarding future immune-therapeutic approaches.
To distinguish between therapy-induced changes, especially with regard to TMZ
cycles, we performed subgroup analyses with two groups (standard, not standard) based
on the received amount of chemotherapy. Interestingly, TAM infiltration was reduced in
recurrent tumors independent of the received therapy. Despite the reduced TAM infil-
tration, the percentage of patients expressing IL8 rose by more than 20% in the recurrent
tumors compared to the primary tumors in both treatment groups. Furthermore, CXCL2
expression was significantly reduced in patients of the not standard group in the recur-
rent tumors whereas CXCL2 expression in patients receiving temozolomide according
to the Stupp protocol was comparable to primary tumors. Additionally, the amount of
CXCL2-expressing TAMs was significantly reduced in the recurrent tumors of the not
standard group, which may account for the reduced amount of CXCL2. These findings
implicate a possible increase in CXCL2 expression after ≥4 cycles of TMZ, if the decrease
in CXCL2-expressing TAMS and CXCL2 itself in the less or no TMZ group (TMZ≤3) could
be considered representative for the natural course of tumor recurrence. This interpretation
would coincide with the previously described upregulation of CXCL2 and IL8 after TMZ
treatment in vitro and in GBM patients [28,31]. However, as we could only include a few
patients without any TMZ treatment (n = 4), this can only be assumed and needs to be
proven in future studies. As TMZ is part of the standard treatment, patients who are not
treated with it are rare and mostly >70 years. This age group is often treated according to
the Nordic glioma protocol [67]. Furthermore, it would be unethical to withhold this part
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of the well-established therapy from GBM patients, especially because median survival
with the standard of care therapy is still only 15 months [2].
3.3. The Influence of TMZ on Central Chemokines in GBM
Most studies on CXCR2 signaling in GBM have focused on IL8 rather than
CXCL2 [25,28,50,68]. In this regard, it is important to mention that IL8 is not expressed
in immunocompetent murine models and CXCL2 has been identified as the respective
IL8 homologue [69]. We showed that CXCL2 is expressed by all patients in primary GBM
tumors while IL8 was only detected in 43% of primary tumors but in 70% of recurrent
tumors. This finding coincides with a recently published study by Hasan et al. [28]. Here,
the authors showed that IL8 was elevated in 65% of 17 matched recurrent GBMs [28]. On
the other hand, Bruyère et al. showed that CXCL2 and CXCR2 were expressed by three out
of four patient-derived GBM cell lines while IL8 was expressed by all of them on the mRNA
expression level [31]. These findings raise the question of whether CXCL2 and IL8 really
exert the exact same functions in GBM patients, or whether they act complementary to
each other. This is of major interest for future studies to understand this signaling pathway
better. Nevertheless, the upregulation of the CXCR2 axis has been shown to be associated
with a reduced overall survival in GBM patients, which further underlines the importance
of this signaling pathway regardless of the binding chemokine [25,26]. Therefore, CXCL2
and IL8 seem be important to fight GBM recurrence. Thus, blocking their mutual receptor
CXCR2 represents a promising target to establish new therapeutic approaches.
3.4. Combination Therapy Leads to Superior Antitumoral Effects Compared to Sole TMZ In Vivo
Combination treatments can outperform any single approach by combining synergistic
effects while lowering the required concentration of each active ingredient to reduce side
effects [51]. As recently shown by our group, intrathecal use of SB reduced tumor volume
in the same syngeneic orthotopic mouse model by 47% [40] but failed to cure the disease.
This again underlines the need for a combined approach. As TAM infiltration affected
primary tumor progression in our study, and CXCR2 antagonization has been shown to
reduce TAM accumulation [40], a combination strategy utilizing a CXCR2 antagonist and
TMZ seemed appealing. In this study, the combined application of SB and TMZ led to a
tumor reduction of 75% within a very homogeneous group while sole TMZ application
reduced tumor volume by 61%. This increase in volume reduction could be best explained
by blockage of CXCR2 signaling in addition to TMZ treatment. Even though there was
no significant difference between the TMZ only and the TMZ + SB group in proliferation
and apoptosis, the ratio of apoptosis to proliferation was only significantly shifted in the
combined treatment group compared to the control and sole TMZ group.
In our previous studies, we reported a reduced vessel density in vivo and diminished
sprouting capabilities of HBMEC in vitro after SB treatment [26,40]. Furthermore, SB is
known to impair the development of VM, which has been shown to be a prognostic marker
for GBM [25,70]. However, we only observed a tendency for decreased tumor vasculariza-
tion after combined treatment. In comparison to our previous study, the antiangiogenic
effect was less distinctive than when SB was administered alone [40]. The major difference
between both set ups was the number of inoculated tumor cells, which was 5-fold higher
in this study. This could have led to a different basis, as in this study, the morphological
properties of the control tumors changed and were reflected in a 1.9-fold higher number of
proliferating cells and only half the TAM numbers.
Despite the relatively small effect of the combination therapy in our study, it is likely
that other treatment protocols and longer observation periods could improve the treatment
efficacy. For instance, cyclic TMZ protocols have led to a superior tumor volume reduction
in comparable GL261 mouse models [71,72]. The treatment period in our study was
restricted to only seven days due to the mini-osmotic pump for SB, since the efficacy of
systemically administered SB has recently been shown to be lower [40]. In this regard,
targeted approaches coupling SB with tumor-specific molecules (L19-SIP, F8-SIP) should
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be implemented to increase the antitumoral efficacy of systemic SB in order to be able to
carry out survival studies [73,74]. Additionally, the value of sequential therapy regimens
should be investigated [75], as the TMZ-induced upregulation of CXCR2 signaling and its
ligands becomes more relevant over time [28,31]. Finally, the radiation therapy, which is
part of the current standard therapy (Stupp protocol) in clinical routine, was not included
in our experimental set-up [2]. However, SB225002 also has a radio-sensitizing effect [76].
Thus, we established an appropriate irradiation set-up to be able to implement irradiation
in the combined treatment approach in the future studies [77].
3.5. Limitations
The major limitation of the patient-associated part was its retrospective design and
selection bias with regard to the primary tumor evaluation as the second surgery for the
recurrence was obligatory. However, this selection was necessary for the aimed direct
matched primary and recurrent tumor evaluation as this was our focus. When comparing
the treatment groups according to the TMZ amount, the lack of a TMZ-naïve main group
must be criticized, but as the number of patients without any TMZ was very low, the
suggested classification based on the amount of TMZ cycles was reasonable to gain first
insights into the potential role of TMZ.
The main limitations of our in vivo study were the small group size and the short
treatment period as discussed above. Nevertheless, this set-up was suitable for providing
initial findings on the tolerability and effectiveness of a combined treatment approach.
4. Materials and Methods
4.1. Human Specimens
We performed a search in our retrospective GBM patient pool to identify patients
that were treated for primary and recurrent GBM with surgical resection. Approval of the
Ethical Committee of Charité–Universitätsmedizin Berlin, Germany was received for the
retrospective assessment of patient data and residual tumor material (application number:
EA1/045/18). All analyses were carried out based on the well-defined guidelines of
good scientific practice working with patient material. According to our inclusion criteria,
all GBM patients that underwent a resection for their primary and recurrent tumors
between 2012 and 2017 at the Department of Neurosurgery, Charité–Universitätsmedizin
Berlin, Germany, were screened. Furthermore, tumors had to be classified as GBM by
two independent neuropathologists according to the latest WHO classification [54,78],
using standard histological markers. A minimum of two months between the first and
second surgery was set as an additional inclusion criterion to define it as recurrence after
the primary tumor resection. Two patients had to be excluded from the analysis due to
the lack of FFPE material. A total of 76 brain tissue samples of 38 patients with matched
primary and recurrent GBM tumors were included in this study (Figure 7a). Clinical
and routine diagnostic parameters, such as patient age, gender, progression-free survival,
overall survival, MGMT-promotor methylation, IDH-1 mutations, and p53 accumulation,
were assessed. Afterwards, detailed immunofluorescence stainings were performed to
further compare primary and recurrent tumors (Figure 7a).
The patients were further divided into two treatment groups, depending on the de
facto received therapeutic regimens for their primary tumors. Patients that were treated by
almost complete standard Stupp protocol for their primary GBM [2], consisting of primary
tumor resection followed by radio-chemotherapy and six cycles of adjuvant chemotherapy,
were classified as the “standard” group. To be able to provide a similar size of the groups
to allow comparisons, ≥4 adjuvant TMZ cycles were included in the standard group
(TMZ≥4). Patients that received ≤3 cycles or temozolomide or none were classified as “not
standard” (TMZ≤3).
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Immunofluorescence Staining of Human FFPE Sections
First, 4-µ -thick FFPE slices of 76 tumor samples were deparaffinized in xylol and
rehydrated in a descending alcohol series. For optimal antigen retrieval, FFPE slices were
pressure cooked in a citrate buffer for 15 min followed by washing steps with aqua bidest
and PBS. After blocking with 0.5%, 1% casein, or 10% goat serum, respectively, the following
primary antibodies were used: polyclonal goat anti-IBA1 (1:100, abcam, Cambridge, UK,
ab5076), polyclonal rabbit anti-CXCL2 (1:100, BIO-RAD, Hercules, CA, USA, AHP773),
monoclonal mouse anti-IL8 (1:100, R&D Systems, Minneapolis, MN, USA, MAB208-100),
polyclonal rabbit anti-VEGF (1:100, abcam, Cambridge, UK, ab1316), polyclonal rabbit
anti-CXCR2 (1:100, abcam, Cambridge, UK, ab14935), and polyclonal mouse anti-CD31
(1:25, R&D Systems, Minneapolis, MN, USA, BBA7). For the anti-IBA1, anti-CXCL2, and
anti-IL8 staining, the Autofluorescence Eliminator Reagent (Millipore, Burlington, MA,
USA) was applied according to the manufacturer´s instructions. Slices were incubated with
primary antibodies for 2 h followed by several washing steps and treatment with respective
secondary antibodies (Alexa Fluor®647 donkey anti-goat, 1:200; CyTM3 donkey anti-rabbit,
1:200; rhodamine red conjugated donkey anti-mouse, 1:200; fluorescein conjugated donkey
anti-rabbit, 1:200; all Jackson ImmunoResearch Europe Ltd., Ely, UK) for 1.5 h. All slides
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were covered with DAPI-containing mounting medium (Dianova, Hamburg, Germany)
and sealed with cover slips.
Images were acquired with a 20× magnifying objective using a fluorescence micro-
scope (Zeiss, Axio Observer Z1, Zeiss MicroImaging GmbH, Jena, Germany). ImageJ 1.53c
(available from: http://imagej.nih.gov/ij, accessed on 28 June 2020) was used to analyze
images. In total, 5–22 images from each patient derived from throughout the whole avail-
able tumor area were analyzed. For the subgroup analysis of TAM infiltration, the mean
of all patients was defined as the limit for patients with low infiltration (<520 cells/mm2).
The group with >520 TAMs was further divided into high (520–1000 cells/mm2) and very
high infiltration (>1000 cells/mm2).
4.2. In Vivo Animal Model
4.2.1. Tumor Cells
For tumor initiation, we used murine GL261 cells. Prior to inoculation, cells were
cultured for three days in Dulbecco’s Modified Eagle Medium supplemented with 1%
Streptomycin/Penicillin and 10% fetal bovine serum at 5% CO2 at 37 ◦C. The cells were
harvested at around 70% confluence for the inoculation.
4.2.2. Animals and Set-Up
All experiments were conducted according to German Law for Animal Protection
under the permission number G0221/17 controlled by LaGeSo Berlin. Additionally, AR-
RIVE Guidelines were followed. A syngeneic mouse model with GL261 glioblastoma cells
was used. Animals (C57BL6N, female, 11 weeks, 20–24 g) were kept in 12 h light–dark
cycle, fed and watered ad libitum. Animals were checked daily for neurological symptoms
and changes in weight. Animals received intraperitoneally administered anesthesia in
standard dosages (9 mg Ketamine-Hydrochloride + 1 mg Xylazine per 100 g) for tumor
cell inoculation, mini-osmotic pump implantation, and perfusion. Additionally, mice
received infection prophylaxis (Benzylpenicillin-Natrium, InfectoPharm®, Heppenheim,
Germany) and analgesic protection (Paracetamol, B.Braun, Mesungen, Germany) during
the procedures.
The experimental set up used in this study was based on the timeline described
previously [40]. In brief, the investigation period lasted 21 days and started with tumor
cell inoculation on day 0. A total of 1 × 105 GL261 cells were stereotactically inoculated
into the right striatum (2 mm lateral, 1 mm anterior, and 3 mm deep to the Bregma) using a
1 µL Hamilton syringe. After verification of tumor size by MRI, the treatments were
initiated on day 14. After a treatment period of seven days, MRI was conducted again to
analyze the tumor growth before sacrificing animals for further analyses (Figure 7b).
4.2.3. Treatments
SB was administered intrathecally as recently described [40]. In short, a mini-osmotic
pump (model 2002/2001; ALZET, DURECT Corporation, Cupertino, CA, USA) was pre-
pared and filled with the small molecule CXCR2 Antagonist SB225002 (Tocris, Bristol,
UK) according to the manufacturer’s protocol prior to implantation on day 14. The intra-
ventricular catheter was placed 0.8 mm laterally of the bregma into the lateral ventricle
contralateral to the tumor site and a subcutaneous pocket was prepared for mini-osmotic
pump reservoir placement. Treatments started immediately with implantation of a mini-
osmotic pump on day 14. SB was administered continuously with a rate of 1 µL per hour
at a dosage of 30 µg per day.
The intraperitoneal administration of TMZ (TEMODAL®, MSD, Kenilworth, NJ, USA)
was conducted daily with a weight-adapted dosage of 60 µg/g/d. The control group
received Aqua ad iniectabilia (B.Braun, Mesungen, Germany) intraperitoneally.
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4.2.4. MRI
Tumor volume was measured using a 7 Tesla small animal MRI (Pharmascan 70/16AS,
Bruker BioSpin, Ettlingen, Germany and Paravision 5.1 software) and a 20 mm inner
diameter quadrature volume resonator (Rapid Biomedical, Rimpar, Germany). Mice
received inhalation anesthesia using 1.5–2.0% isoflurane (cp-pharma, Burgdorf, Germany)
in a mixture of oxygen and nitrous oxide (30%/70%) and were placed on a heating plate to
maintain body temperature. For continuous monitoring during MRI, respiratory frequency
was measured. T1-weighted sequence (TR/TE = 800/10.6 ms, RARE factor 2, 4 averages)
with contrast agent (Gadolinium, Magnevist®, Bayer AG, Leverkusen, Germany) and
T2-weighted sequence (TR/TE = 4200/36 ms, RARE factor 8, 4 averages) was conducted.
Volumes were measured by Analyze 10.0 (Analyze 10.0, AnalyzeDirect, Inc., Overland
Park, KS, USA).
4.2.5. Tissue Harvesting and Preparation for Analysis
Prior to brain harvesting on day 21, animals were anaesthetized and then perfused
intracardially with Paraformaldehyde (PFA) 4% in PBS (phosphate-buffered saline) or
sterile PBS alone. To prepare immunofluorescence staining, brains were post-fixed in 4%
PFA for 24 h following by sucrose dehydration before freezing and storing at −80 ◦C. In
preparation for PCR analysis, PBS-perfused brains were processed under the microscope
to resect tumor tissue as well as contralateral control tissue microsurgical. Both were shock
frozen in liquid nitrogen and stored at −80 ◦C until proceeding with tissue homogenization
for RNA extraction.
4.2.6. Immunofluorescence Staining of Mouse Brain Sections
Frozen brains were cut into 10 µm sections at a temperature of −29 ◦C (Thermo
Scientific (Microm HM 560), Waltham, MA, USA) before staining for proliferation, apopto-
sis, vasculature, and TAM accumulation according to standard protocols. Apoptosis was
stained according to the manufacturer’s recommendations using a TUNEL Kit (TUNEL,
ApopTag red In situ kit (S7165), Merck Millipore, Darmstadt, Germany) followed by prolif-
eration (rabbit anti-KI67, Thermo Fisher Scientific (RM-9106-S1), Waltham, MA, USA; 1:200,
16 h, 4 ◦C) staining in a combined protocol. The other primary antibodies were used as
listed: TAMs (rabbit anti-IBA1, Wako Chemicals (019-19741), Richmond, VA, USA; 1:200);
endothelial cells (rat anti-CD31, BD Pharmingen (550274); 1:50, 16 h, 4 ◦C); CXCL2 (goat,
R&D Systems (AF-452-NA), Minneapolis, MN, USA; 1:20, 16 h, 4 ◦C), and CXCR2 (rabbit,
abcam (ab14935), Cambridge, UK; 1:200, 48 h, 4 ◦C).
All secondary antibodies (Alexa Fluor® 647 donkey anti rabbit, Jackson ImmunoRe-
search (711-605152); CyTM3 donkey anti-rat, Jackson ImmunoResearch (712-165-153);
Alexa Fluor® 647 donkey anti-goat, Jackson ImmunoResearch (705-605-147); West Grove,
PA, USA) were used at a concentration of 1:200 for 90–120 min at room temperature solved
in Casein 0.5% in PBS. The final step of all protocols included staining of nuclei with DAPI
(Dianova, Hamburg, Germany) and subsequently covering slides for immunofluorescence
microscopy. To obtain a comprehensive overview of the tumor area, images were taken of at
least three sections of different regions per animal and per staining. Images were acquired
as earlier described with a 20× magnifying objective using a fluorescence microscope and
ImageJ 1.53c was used to analyze images.
4.2.7. RNA Isolation and Quantitative Real-Time PCR
RNA from tumor-bearing mice was isolated from homogenized tumor tissue as well
as contralateral parenchyma of the control group using a RNeasy Kit (QIAGEN, Hilden,
Germany) according to the manufacturer’s protocol. RNA concentration and quality was
measured with a plate photometer (Infinite M200, Tecan, Männedorf, Switzerland) prior to
eradication of genomic DNA contamination. cDNA synthesis of tumor tissue as well as
contralateral parenchyma was carried out with 500 ng RNA using the PrimeScriptTMRT
reagent Kit with gDNA Eraser (TaKaRa, Cat. #RR047A, Shiga, Japan) according to the man-
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ufacturer’s instructions. The cDNA quantity was measured by photometry. Quantitative
Real-time-PCRs (qRT-PCRs) were executed for Cxcr2, Cxcl2, Cxcr1, Bax, Bcl-2, Vegf, Vegfr1,
and Vegfr2 using triplicates in a 10 µL reaction volume and the TB GreenTM Premix Ex
TaqTM Kit (TaKaRa, Shiga, Japan). 18S was used as the reference gene. Primer sequences
can be found in the Supplementary Materials Table S3. qRT-PCRs were performed with the
Quant Studio 6 Flex System (Thermo Scientific, Waltham, MA, USA). Target expression
levels were normalized to 18S mRNA. The relative quantification method (∆∆Ct) was used
for analyses.
4.3. Statistical Analysis
Statistical analyses were performed using GraphPad Prism Software (v9.1.1, San
Diego, CA, USA) and IBM SPSS Statistics (Version 26.0 Armonk, NY, USA, IBM Corp.).
Data was presented as mean ± standard deviation (SD) or/and median with (1st and
3rd quartile). The mean of the mean per group was used for the immunofluorescence
analyses. Primary and recurrent tumors were compared by two-tailed unpaired Student´s
t-test, while a two-tailed paired Student´s t-test was performed for the analysis of primary
and recurrent tumors within the same treatment groups, and mean differences and the
95% confidence interval of these tests are presented as indicated. Differences in murine
treatment groups were first analyzed by one-way ANOVA to detect if any significant
changes existed amongst the groups. If there was a significance in ANOVA analysis, single
comparisons with Bonferroni correction were applied and significant results are reported.
Due to the exploratory character of this study, p-values and confidence intervals were not
adjusted for multiplicity (except pairwise comparisons after ANOVA). The overall survival
and progression-free survival were investigated using Kaplan–Meier analysis followed
by log-rank-test to compare groups. In order to assess the relevance of multiple factors,
univariable and multiple analyses were performed using Cox regression analyses. Multiple
analysis was carried out for all variables with p ≤ 0.2 in the univariable analysis. Pearson’s
correlation coefficient was used to determine the association between the expression levels
of different proteins. A p value ≤ 0.05 was considered as significant. For better readability,
we only stated p values ≤ 0.055 in the text to highlight the significant or almost significant
results.
5. Conclusions
To our knowledge, this is one of the largest series comparing matched GBM tumors.
We identified TAM infiltration as a negative predictor of OS in GBM. Our in-depth analysis
of matched GBM tumors showed that primary tumors were highly infiltrated by TAMs
in comparison to recurrent tumors and that a very high TAM infiltration drives primary
tumor progression. Interestingly, TMZ treatment partially altered vascular parameters,
IL8 and CXCL2 expression in GBM patients. In order to fully elucidate the in vivo effect
of TMZ with a focus on TAMs and the important signaling pathways in GBM patients,
further prospective studies are warranted.
Our novel therapeutic approach combining TMZ with CXCR2 antagonization in vivo
was well-tolerated and led to decreased tumor volumes despite the short treatment period
of only seven days. Thus, this study provides promising first insights into this combination
treatment. The full efficacy of this combinational approach should be investigated in
further preclinical studies with a longer observation period.
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